Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center. The study is the largest systematic review evaluating the risk of developing any malignancy among rheumatoid arthritis patients using approved biologic response modifiers (BRMs), several of which include tumor necrosis factor (TNF) inhibitors. Read more here.
Study mentioned: Lopez-Olivo MA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012 Sep 5;308(9):898-908. PMID: 22948700
No comments:
Post a Comment